ReAlta’s Pegtarazimod Demonstrates Potential in Reducing Brain Inflammation in Newborn HIE Study
ReAlta Life Sciences has announced significant findings from a preclinical study published in the American Journal of Perinatology, highlighting the potential of RLS-0071 (pegtarazimod) to reduce brain inflammation in newborns with hypoxic ischemic encephalopathy (HIE). The study reveals that pegtarazimod effectively lowers levels of microglia, myeloperoxidase (MPO), and reactive oxygen species (ROS), key factors in […]